$REGN

Generating a unique summary for REGN…

AI-generated for information only — not investment advice.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Institutions hold 93.28% · insiders 2.08% · 1,958 institutions

Consensus score 1.82 (1 = strong buy, 5 = sell) · mean target 867.33

• TD CowenBuymain2026-10-21
• Piper SandlerOverweightmain2026-10-19
• UBSBuyup2026-10-15
• RBC CapitalSector Performmain2026-10-08
• Truist SecuritiesBuymain2026-10-07
• Morgan StanleyEqual-Weightmain2026-10-07
• JP MorganOverweightmain2026-10-06
• JefferiesBuymain2026-10-01
• Argus ResearchBuyup2026-10-01
• RBC CapitalSector Performreit2026-09-29

Next report: 2026-10-30

• 8-KCorporate Changes & Voting Matters2026-10-06Open
• 8-KCorporate Changes & Voting Matters2026-09-30Open
• N-PXAnnual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX2026-08-20Open
• 8-KCorporate Changes & Voting Matters2026-07-30Open
• 8-KCorporate Changes & Voting Matters2026-07-06Open
• 8-KCorporate Changes & Voting Matters2026-06-17Open
• 10-QPeriodic Financial Reports2026-04-29Open
• ARSAnnual Report to Shareholders2026-04-24Open
• 8-KCorporate Changes & Voting Matters2026-04-08Open
• 10-KPeriodic Financial Reports2026-02-04Open

• 1 safe-and-steady stock with exciting potential and 2 facing headwinds

  A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

  Fri, 23 Oct 2026 16:56:39 +0000

• Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

  Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  Fri, 23 Oct 2026 13:00:10 +0000

• Are You Overpaying For Regeneron Stock Versus Its Rivals?

  For questions about this article or underlying research, email help@trefis.com.

  Wed, 21 Oct 2026 21:18:41 +0000

• Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results

  Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its “Partners Fund”. The letter can be downloaded here. Coming into this year, the Fund’s three-year annualized returns were at 11.7%, but recent performance, particularly this year and in Q3, has raised concerns about the investment strategy. The Fund returned 2.41% in […]

  Tue, 20 Oct 2026 02:16:47 +0000

• How Much Upside Is Left In Regeneron Stock?

  Regeneron Pharmaceuticals (REGN) stock returned 37.9% in the year to October 16, 2026. This easily outpaced the 16.2% gain for the S&P 500 and left investors looking at a higher price. The underlying business has grown faster lately, yet its operating margin has slipped in each of the past three years. If you buy or hold the shares today, what could three more years of owning them make you.

  Mon, 19 Oct 2026 17:16:14 +0000

• Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

  Regeneron's biggest growth driver still has plenty of fuel left in the tank.

  Sat, 17 Oct 2026 19:44:00 +0000

• Did Earnings Beat Just Shift Regeneron Stock Investment Narrative?

  Regeneron Pharmaceuticals reported Q2 revenue of US$4.29b, up 16.7% year on year, alongside positive 84 week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva. The data supports its recently approved use in reducing new heterotopic ossification lesions and flare ups. The 84 week OPTIMA readout suggests a sustained effect in limiting new rogue bone formation and flare ups while maintaining a generally consistent safety profile. This could reinforce...

  Fri, 16 Oct 2026 05:20:03 +0000

• Regeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative Holds

  Regeneron Pharmaceuticals (REGN) shares have been in focus after the company reported quarterly revenue of US$4.29b, up 16.7% year on year. The results beat analyst expectations and have lifted the stock about 12.4% since the release. Regeneron Pharmaceuticals has been in a strong upswing, with a 7-day share price return of 7.68% and a 90-day share price return of 17.68%. The 1-year total shareholder return of 40.63% reflects momentum that has built over time as new drug data, expanded...

  Thu, 15 Oct 2026 22:11:58 +0000